Pangenomic Health Inc. (NARA.CN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-135.1%

-CA$0.06

vs CA$0.17 price

Levered DCF

-CA$0.01

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-346.8

Distress zone

Rating

—

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-2.42×	-0.17×	-3.33×	-6.16×	-9.33×	-52.08×	-2,118.64×
P/B	-3.87×	-0×	-4.66×	-343.92×	11.02×	668.83×	3,002.05×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-2.53×	-0.09×	-4.03×	-20.75×	-27.57×	-4,045.5×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.07×	0.02×	0.03×	0.67×	4.99×	1.08×	1.77×
Debt / equity	-0.1×	0×	-0.45×	-0.47×	0×	2.51×	0×
Interest coverage	-835.72×	-0.02×	-61.58×	-2,776.03×	-345.83×	-41.29×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	156.8%	0.2%	138.6%	9459.3%	-118.3%	-1278.2%	-140.9%
Return on invested capital	173.2%	0.0%	229.8%	3211.1%	-38.0%	-355.8%	-2.9%
Return on assets	-2132.5%	-9.7%	-4159.2%	-4036.2%	-102.9%	-95.1%	-61.3%
Free cash flow yield	-22.2%	-8929.0%	-15.7%	-3.8%	-4.3%	-0.5%	-0.0%
Earnings yield	-40.5%	-582.9%	-29.8%	-27.5%	-10.7%	-1.9%	-0.0%
Enterprise value	CA$8.7M	-CA$654.6	CA$10.9M	CA$74M	CA$23.4M	CA$7.3M	CA$7.3M
Net debt / EBITDA	-0.05×	-0.18×	-0.35×	-0×	1.59×	5.93×	0×
Cash conversion cycle (days)	-571,134	-705,743	-428	-12,313	-29,309	0	0